Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]) and Sanofi-aventis (NYSE: [[ticker:SNY]]) of France announced in a press release that their investigational drug aflibercept (Zaltrap) met its primary survival endpoint in a Phase III trial. The drug was tested as a second-line treatment in patients with colorectal cancer that had spread. “These findings are exciting given the limited second-line treatment options for patients with metastatic colorectal cancer,” George Yancopoulos, chief scientific officer of Regeneron and President of Regeneron Research Laboratories, said in the statement. The company plans to release details about the study at an upcoming medical meeting and to apply for FDA approval in the second half of the year.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
